Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. About MedincellMedincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Medincell's investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. Medincell's BEPO technology is licensed to Teva as SteadyTeq, a trademark of Teva Pharmaceuticals.